Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The condition being studied is metastatic pancreatic ductal adenocarcinoma, an advanced form of pancreatic cancer that has spread to other parts of the body. The experimental treatment combines an intravenous antibody called Telisotuzumab adizutecan with a chemotherapy regimen known as FOLFOX, which contains fluorouracil, calcium folinate, and oxaliplatin. For comparison, participants may receive the usual standard of care that can include irinotecan together with the same chemotherapy drugs.

The main goal of the trial is to determine whether the new combination is safe and works better than current therapies. Participants will receive the assigned medicines by IV infusion in repeated cycles, with regular hospital visits for the infusions and for medical checks. Throughout the study, doctors will look for signs that tumors shrink, known as objective response, and will track how long patients live, referred to as overall survival.

After random assignment to either the experimental group or the standard‑care group, treatment continues for several weeks while imaging scans, blood tests, and questionnaires are used to assess tumor size, side effects, and quality of life. The study also measures how long the disease stays under control without getting worse, called progression‑free survival, before participants are followed for long‑term survival outcomes.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline evaluation

    After enrollment, a complete medical history, physical examination, laboratory tests and imaging studies are performed to document the current condition.

    The purpose is to create a reference point for later comparison with future assessments.

  2. Step 2

    First treatment administration

    On the first scheduled day, the patient receives four intravenous (iv) infusions:

    telisotuzumab adizutecan (dose 00 mg as defined in the protocol),

    fluorouracil (dose 00 mg iv),

    calcium folinate (dose 00 mg iv), and

    oxaliplatin (dose 00 mg iv).

    Each medicine is given through a vein using a drip pump, following the timing and order specified in the study protocol.

  3. Step 3

    Repeated treatment cycles

    Subsequent cycles of the same four iv infusions are given according to the schedule defined in the protocol.

    The patient returns to the clinic for each cycle, receives the medicines, and is monitored throughout the infusion.

    Treatment continues until the protocol‑specified end point, disease progression, or unacceptable side effects.

  4. Step 4

    Regular monitoring visits

    Before each infusion, blood tests are drawn to check organ function and blood counts.

    A brief physical examination is performed to assess any new symptoms.

    The clinical staff records any side effects and adjusts care as needed.

  5. Step 5

    Imaging assessments

    At intervals defined by the protocol, imaging studies such as CT scans are performed to evaluate tumor response.

    The results are compared with the baseline evaluation to determine whether the cancer is shrinking, stable, or growing.

  6. Step 6

    End of treatment evaluation

    After the final scheduled infusion, a comprehensive assessment is carried out.

    This includes a physical exam, laboratory tests, and imaging to document the disease status at the end of therapy.

  7. Step 7

    Post‑treatment follow‑up

    The patient continues to be seen at scheduled visits after treatment has stopped.

    Follow‑up visits include blood tests, physical examinations and imaging as required by the protocol to monitor overall survival and long‑term safety.

Who can join the trial?

4 criteria

  • Have a type of pancreatic cancer called adenocarcinoma that cannot be removed by surgery (unresectable) and has spread to other parts of the body (metastatic), and this diagnosis must be confirmed by looking at the cancer cells under a microscope (histologically‑ or cytologically‑confirmed).
  • Be able to perform daily activities with a score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance status scale, where 0 means fully active and 1 means able to do light work but not fully active.
  • Agree to let the study team use a stored or recently taken sample of your tumor tissue (tumor tissue) for testing during the screening process.
  • Have tumors that can be measured on scans, using the rules called Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, which help doctors track how the cancer changes over time.

Who cannot join the trial?

7 criteria

  • Having any previous chemotherapy, hormone therapy, targeted drug treatment, major surgery, or radiation (except low‑dose comfort‑care radiation) for cancer that could not be removed or had spread to other parts of the body.
  • Having taken medicines that specifically block the c-MET protein, which is a type of targeted cancer therapy.
  • Having a past or current lung problem called interstitial lung disease (ILD) or pneumonitis that needed treatment with strong anti‑inflammatory drugs (systemic steroids), or any sign of an active lung problem on a screening chest scan (CT). This includes conditions such as:
    • idiopathic pulmonary fibrosis – a scar‑forming lung disease with unknown cause,
    • organizing pneumonia (for example, bronchiolitis obliterans) – a type of lung inflammation that can block small airways,
    • drug‑induced pneumonitis – lung inflammation caused by medicines,
    • idiopathic pneumonitis – lung inflammation with no known cause.
    • Having had a bone‑marrow transplant, a solid‑organ transplant (such as kidney, liver, or heart), or a previous medical diagnosis of tuberculosis (a bacterial infection that mainly affects the lungs).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Telisotuzumab adizutecan

    is an experimental antibody given by IV infusion. It is designed to attach to certain proteins on cancer cells and help the immune system recognize and attack those cells. In this study it is tested together with other chemotherapy drugs to see if it improves safety and how well it works against pancreatic cancer.

  • Fluorouracil

    is a chemotherapy medicine that is given through an IV. It works by stopping cancer cells from making DNA, which prevents them from growing and dividing. In the trial it is part of the standard chemotherapy combination used for treating pancreatic cancer.

  • Oxaliplatin

    is a chemotherapy drug given by IV infusion. It contains platinum, which damages the DNA inside cancer cells and leads to cell death. It is used together with other drugs in the standard treatment regimen for pancreatic cancer.

  • Calcium folinate

    (also known as leucovorin) is a vitamin‑like substance given intravenously. It does not kill cancer cells by itself, but it makes fluorouracil work better by helping it stay inside cancer cells longer. It is included in the standard chemotherapy mix for pancreatic cancer.

  • Irinotecan

    is a chemotherapy agent administered by IV. It interferes with an enzyme that cancer cells need to copy their DNA, which stops the cells from growing. In this study it is listed as a comparator treatment that may be used as part of the standard care options.

What is already known about the treatment

  • Calcium Folinate

    This drug is given by intravenous infusion. It is an established medication that is widely used in cancer treatment and is well described in medical literature. It helps improve the effect of fluorouracil and reduces side effects of some other drugs by supplying a form of folic acid that cells need to make DNA. It belongs to the class of folate analogs and is called a rescue agent.

  • Irinotecan

    Irinotecan is administered through an intravenous drip. It is an approved chemotherapy drug that has been studied for many years in cancers such as colorectal and pancreatic cancer. After it enters the body it is changed into an active form that blocks an enzyme called topoisomerase I, stopping cancer cells from copying their DNA. It is classified as a topoisomerase I inhibitor.

  • Fluorouracil

    Fluorouracil is given by intravenous injection. It is a long‑standing chemotherapy agent used for many solid tumors, including pancreatic cancer. The drug looks like the normal building block uracil and interferes with DNA synthesis by blocking the enzyme thymidylate synthase. It is classified as an antimetabolite and a pyrimidine analog.

  • Oxaliplatin

    Oxaliplatin is delivered as an intravenous infusion. It is an approved platinum‑based chemotherapy that is commonly used in colorectal and pancreatic cancer regimens. The medication creates cross‑links in the DNA of cancer cells, which prevents the cells from dividing and leads to their death. It belongs to the class of platinum compounds, a type of alkylating agent.

  • Telisotuzumab Adizutecan

    This investigational drug is given by intravenous infusion as a solution for infusion. It is currently being studied in clinical trials and has not yet received regulatory approval. The medication works by attaching to a protein called c‑Met on the surface of cancer cells and delivering a cell‑killing payload directly to those cells. It is classified as an antibody‑drug conjugate that targets c‑Met.

Investigated diseases

Metastatic pancreatic ductal adenocarcinoma - Metastatic pancreatic ductal adenocarcinoma is a cancer that begins in the cells lining the main ducts of the pancreas and has spread to other parts of the body. The disease often starts without clear symptoms, and as it grows it can cause abdominal pain, weight loss, and digestive problems. Cancer cells travel through the bloodstream or lymph system, forming new tumors in organs such as the liver, lungs, or peritoneum. As more sites become involved, the overall burden of disease increases, leading to further decline in organ function.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2025-522563-15-00Protocol codeM25-288Estimated enrolment900 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.